6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Autor: Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris Pauporté, Celine Faure-Mercier, Sophie Paget-Bailly, Julie Henriques, Jean Marie Grouin, C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, JL Bréau, AK Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, JL Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, AF Dillies, X Durando, JP Ferrière, C Mouret-Reynier, JM Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, AC Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, JP Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, JM Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, JM Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, JC Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, G Sadki-Benaoudia, A Marti, AL Villing, B Slama, JL Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, MJ Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, JC Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, JF Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, JF Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, P Nouyrigat, S Clippe, MC Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, D Fric, C Garnier, C Leyronnas, T Kreitman, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, JF Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, JP Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, JC Legueul, J Mandet, D Besson, AC Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, JM Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, CB Levaché, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, GA Baumont, M Bégue, S Gréget, JL Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, JL Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, JP Chantelard, GA L'Helgoualc'h, EC Antoine, A Kanoui, JF Llory, JM Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, N Barbet, N Dohollou, K Yakendji

Publikováno v: Lancet (London, England). 393(10191)

Summary Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned fin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a38de46b67775457b35c99536d038418
https://pubmed.ncbi.nlm.nih.gov/31178155

Abstract P5-10-05: A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)

Autor: J-F Berdah, Daniel Serin, Frank Priou, E. Teissier, P. Piedbois, B. Audhuy, M. Mousseau, C. Delbaldo, S. Greget, E. Quinaux

Publikováno v: Cancer Research. 70:P5-10

The risk of relapse after local therapy remains unacceptable for the majority of patients with early stage breast cancer. Adjuvant chemotherapy has been shown to prolong both disease-free survival (DFS) and overall survival. Several large phase III t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::222c2393ef8851cd23874006c4c6f3ea
https://doi.org/10.1158/0008-5472.sabcs10-p5-10-05

20th Annual Meeting: Association for Oncology of the Upper Rhine (AOR) / Groupe de Travail des Oncologues du Rhin Supérieur (GTOR) / Oberrheinische Arbeitsgemeinschaft für Onkologie (OAO),Colmar, January 16–17, 2004

Autor: B. Audhuy

Publikováno v: Oncology Research and Treatment. 26:599-606

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ccd4fcee166c874c04228592701e309e
https://doi.org/10.1159/000076084

Contents Vol. 26, 2003

Autor: V. Steil, U. Göbel, B. Schüll, L.J. Vlahos, Halle H.-J. Schmoll, J.R. Kouvaris, B. Schymura, A. Kondi-Pahpiti, H. Röckmann, J. Beyer, L. Edler, L. Jost, T. Müller, L. Bauer, W. Scheithauer, P. Herschbach, M. Friedrich, D. Schadendorf, R. Axt-Fliedner, C. Thomeczek, A. Kopp-Schneider, J.G. Meran, F. Egli, K. Diedrich, H. Pape, U. Kraus-Tiefenbacher, M.L. Hansis, H. Fahmüller, S. Krämer, M. Paulussen, H. Hollenhorst, S. Sehlen, P. Moosmann, F. Wenz, W.-D. Ludwig, R.A. Stahel, J.D. Kokakis, G.V. Kornek, R. Song, B. van Kaick, F. Melchert, M. Hildebrandt, U. Aydemir, V.E. Kouloulias, B. Audhuy, H.J. Laws, R. Sylvester, M. Lenk, Nijmegen C.J.A. Punt, E. Dühmke, R. Felberbaum

Publikováno v: Oncology Research and Treatment. 26:III-VII

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f31622e9d91679a486911208c5d0c3df
https://doi.org/10.1159/000076094

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)

Autor: M. Janvier, A Guillot, Claude Linassier, J P Labat, Henri Roché, F Feuilhade, Pierre Pouillart, Patrice Viens, Michel Fabbro, Thierry Delozier, M. Mousseau, Jean-Marc Ferrero, Jocelyne Jacquemier, B Costa, Valérie-Jeanne Bardou, Hervé Curé, Thao Palangie, B Audhuy, F Rousseau, R. Delva

Publikováno v: British Journal of Cancer

Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is still poor. In this work, we evaluate response and toxicity of high-dose sequential chemothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e344e7acebffe2be367aa076ce98f0de
http://europepmc.org/articles/PMC2362932